406 related articles for article (PubMed ID: 14586385)
21. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.
Fukasawa T; Suzuki A; Otani K
J Clin Pharm Ther; 2007 Aug; 32(4):333-41. PubMed ID: 17635335
[TBL] [Abstract][Full Text] [Related]
22. The use of human hepatocyte cultures to study the induction of cytochrome P-450.
Kostrubsky VE; Ramachandran V; Venkataramanan R; Dorko K; Esplen JE; Zhang S; Sinclair JF; Wrighton SA; Strom SC
Drug Metab Dispos; 1999 Aug; 27(8):887-94. PubMed ID: 10421615
[TBL] [Abstract][Full Text] [Related]
23. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Niemi M; Kivistö KT; Diczfalusy U; Bodin K; Bertilsson L; Fromm MF; Eichelbaum M
Pharmacogenet Genomics; 2006 Aug; 16(8):565-8. PubMed ID: 16847425
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
25. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
26. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
29. Expression and induction of CYP3As in human fetal hepatocytes.
Matsunaga T; Maruyama M; Harada E; Katsuyama Y; Sugihara N; Ise H; Negishi N; Ikeda U; Ohmori S
Biochem Biophys Res Commun; 2004 May; 318(2):428-34. PubMed ID: 15120618
[TBL] [Abstract][Full Text] [Related]
30. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.
Markowitz JS; Donovan JL; DeVane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
JAMA; 2003 Sep; 290(11):1500-4. PubMed ID: 13129991
[TBL] [Abstract][Full Text] [Related]
31. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.
Feng HJ; Huang SL; Wang W; Zhou HH
Br J Clin Pharmacol; 1998 Jan; 45(1):27-9. PubMed ID: 9489590
[TBL] [Abstract][Full Text] [Related]
32. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans.
Hirota N; Ito K; Iwatsubo T; Green CE; Tyson CA; Shimada N; Suzuki H; Sugiyama Y
Biopharm Drug Dispos; 2001 Mar; 22(2):53-71. PubMed ID: 11745908
[TBL] [Abstract][Full Text] [Related]
33. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
[TBL] [Abstract][Full Text] [Related]
34. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.
Yasui N; Otani K; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1996 May; 59(5):514-9. PubMed ID: 8646822
[TBL] [Abstract][Full Text] [Related]
35. Rifampin drastically reduces plasma concentrations and effects of oral midazolam.
Backman JT; Olkkola KT; Neuvonen PJ
Clin Pharmacol Ther; 1996 Jan; 59(1):7-13. PubMed ID: 8549036
[TBL] [Abstract][Full Text] [Related]
36. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
[TBL] [Abstract][Full Text] [Related]
37. Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects.
Wennerholm A; Allqvist A; Svensson JO; Gustafsson LL; Mirghani RA; Bertilsson L
Eur J Clin Pharmacol; 2005 Apr; 61(2):113-8. PubMed ID: 15806426
[TBL] [Abstract][Full Text] [Related]
38. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes.
Drocourt L; Pascussi JM; Assenat E; Fabre JM; Maurel P; Vilarem MJ
Drug Metab Dispos; 2001 Oct; 29(10):1325-31. PubMed ID: 11560876
[TBL] [Abstract][Full Text] [Related]
39. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
Dixit V; Hariparsad N; Li F; Desai P; Thummel KE; Unadkat JD
Drug Metab Dispos; 2007 Oct; 35(10):1853-9. PubMed ID: 17639026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
